Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 519-525

  Ray, Nicola J ^a   Miyasaki, Janis M ^a   Zurowski, Mateusz ^a   Ko, Ji Hyun ^a   Cho, Sang Soo ^a   Pellecchia, Giovanna ^a   Antonelli, Francesca ^a   Houle, Sylvain ^a   Lang, Anthony E ^a   Strafella, Antonio P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dopamine agonists; Impulsivity; Parkinson's disease; Pathological gambling

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ISOREMOXIPRIDE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

ADULT; ANTERIOR CINGULATE; ARTICLE; BARRATT IMPULSIVITY SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; IMPULSIVENESS; MESENCEPHALON; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; REWARD; SINGLE DRUG DOSE; TASK PERFORMANCE;

DOPAMINE; DOPAMINE AGONISTS; GAMBLING; HOMEOSTASIS; HUMANS; MESENCEPHALON; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOPHARMACEUTICALS; SALICYLAMIDES;

EID: 84865300674     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.021     Document Type: Article

References (61)

1. Blum K., Chen T.J.H., Meshkin B., et al. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med. Hypotheses 2007, 69(5):1054-1060.
2. Bolan E.A., Kivell B., Jaligam V., et al. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 2007, 71(5):1222-1232.
3. Buckholtz J.W., Treadway M.T., Cowan R.L., et al. Dopaminergic network differences in human impulsivity. Science 2010, 329(5991):532.
4. Campbell-Meiklejohn D., Wakeley J., Herbert V., Cook J., Scollo P., Ray M.K., Selvaraj S., Passingham R.E., Cowen P., Rogers R.D. Serotonin and dopamine play complementary roles in gambling to recover losses. Neuropsychopharmacology 2011, 36(2):402-410. (Jan).
5. Chernoloz O., El Mansari M., Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009, 34(3):651-661.
6. Chiodo L.A., Bannon M.J., Grace A.A., Roth R.H., Bunney B.S. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience 1984, 12(1):1-16.
7. Cilia R., Ko J.H., Cho S.S., et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol. Dis. 2010, 39(1):98-104.
8. Collins D.L., Neelin P., Peters T.M., Evans A.C. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J. Comput. Assist. Tomogr. 1994, 18(2):192-205.
9. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41(11):1431-1441.
10. Domesick V.B. Neuroanatomical organization of dopamine neurons in the ventral tegmental area. Ann. N. Y. Acad. Sci. 1988, 537:10-26.
11. Fallon J.H. Topographic organization of ascending dopaminergic projections. Ann. N. Y. Acad. Sci. 1988, 537:1-9.
12. Farde L., Suhara T., Nyberg S., et al. A PET-study of [11C] FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997, 133(4):396-404.
13. Frank M.J., Samanta J., Moustafa A.A., Sherman S.J. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007, 318(5854):1309-1312.
14. Goldstein R.Z., Volkow N.D. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat. Rev. Neurosci. 2011, 12(11):652-669.
15. Goldstein R.Z., Woicik P.A., Maloney T., et al. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(38):16667-16672.
16. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997, 6(4):279-287.
17. Jang J.Y., Jang M., Kim S.H., Um K.B., Kang Y.K., Kim H.J., Chung S., Park M.K. Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta. J. Neurochem. 2011, 116(6):966-974. (Mar).
18. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002, 58(4 Suppl. 1):S1-S8.
19. Kaasinen V., Någren K., Hietala J., Oikonen V., Vilkman H., Farde L., Halldin C., Rinne J.O. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000, 54(7):1482-1487. (Apr 11).
20. Kessler R.M., Ellis J.R., Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J. Comput. Assist. Tomogr. 1984, 8(3):514-522. (Jun).
21. Khan Z.U., Mrzljak L., Gutierrez A., de la Calle A., Godman-Rakic P.S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(13):7731-7736.
22. Kim S.W., Grant J.E., Potenza M.N., Blanco C., Hollander E. The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res. 2009, 166(1):76-84.
23. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4(3 Pt 1):153-158.
24. Lapish C.C., Kroener S., Durstewitz D., Lavin A., Seamans J.K. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl) 2007, 191(3):609-625.
25. Lee F.J.S., Pei L., Moszczynska A., et al. Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 2007, 26(8):2127-2136.
26. Leeman R.F., Potenza M.N. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) 2012, 219(2):469-490.
27. Montgomery A.J., Asselin M.-C., Farde L., Grasby P.M. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C] FLB 457 PET. J. Cereb. Blood Flow Metab. 2007, 27(2):369-377.
28. Morelli M., Carboni E., Devoto S., Di Chiara G. 6-Hydroxydopamine lesions reduce specific [3H] sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. Eur. J. Pharmacol. 1987, 140(1):99-104.
29. Narendran R., Frankle W.G., Mason N.S., et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C] FLB 457 and [11C] fallypride. Synapse 2009, 63(6):447-461.
30. Nasreddine Z.S., Phillips N.A., Bédirian V., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005, 53(4):695-699.
31. Olsson H., Halldin C., Swahn C.G., Farde L. Quantification of [11C] FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 1999, 19:1164-1173.
32. Paloyelis Y., Asherson P., Mehta M.A., Faraone S.V., Kuntsi J. DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls. Neuropsychopharmacology 2010, 35(12):2414-2426.
33. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 1995, 51(6):768-774.
34. Pitts D.K., Wang L., Kelland M.D., Freeman A.S., Chiodo L.A. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole. J. Pharmacol. Exp. Ther. 1995, 275(1):412-421.
35. Potenza M.N. Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363(1507):3181-3189.
36. Ray N., Strafella A.P. Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging. Clin. EEG Neurosci. 2010, 41(2):87-93.
37. Santiago M., Westerink B.H. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur. J. Pharmacol. 1991, 204(1):79-85.
38. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74(1):1-58.
39. Steeves T.D.L., Miyasaki J., Zurowski M., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132(Pt 5):1376-1385.
40. Subramaniam S., Lucki I., McGonigle P. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res. 1992, 571(2):313-322.
41. Sudo Y., Suhara T., Inoue M., et al. Reproducibility of [11 C] FLB 457 binding in extrastriatal regions. Nucl. Med. Commun. 2001, 22(11):1215-1221.
42. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., Mertens P., Benabid A.L., Pollak P., Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch. Neurol. 2004, 61(11):1705-1709. (Nov).
43. Thobois S., Ardouin C., Lhommée E., et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127. (Apr).
44. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25(15):2649-2653. (Nov 15).
45. Trantham-Davidson H., Neely L.C., Lavin A., Seamans J.K. Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J. Neurosci. 2004, 24(47):10652-10659.
46. van Eimeren T., Pellecchia G., Cilia R., et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75(19):1711-1716.
47. van Eimeren T., Ballanger B., Pellecchia G., et al. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34(13):2758-2766.
48. Vandehey N.T., Moirano J.M., Converse A.K., et al. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J. Cereb. Blood Flow Metab. 2010, 30(5):994-1007.
49. Volkow N.D., Wang G.-J., Fowler J.S., Tomasi D. Addiction circuitry in the human brain (*). Annu. Rev. Pharmacol. Toxicol. 2012, 52:321-336.
50. Volkow N.D., Wang G.-J., Fowler J.S., Tomasi D., Telang F. Addiction: beyond dopamine reward circuitry. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(37):15037-15042.
51. Voon V., Hassan K., Zurowski M., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006, 67(7):1254-1257.
52. Voon V., Dalley J.W. Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy. Nat. Rev. Neurol. 2011, 7(10):541-542.
53. Voon V., Gao J., Brezing C., et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011, 134(Pt 5):1438-1446.
54. Voon V., Mehta A.R., Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 2011, 24(4):324-330.
55. Voon V., Pessiglione M., Brezing C., et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010, 65(1):135-142.
56. Voon V., Sohr M., Lang A.E., et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann. Neurol. 2011, 69(6):986-996.
57. Weintraub D., Koester J., Potenza M.N., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67(5):589-595.
58. Wichers M., Aguilera M., Kenis G., et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology 2008, 33(13):3030-3036.
59. Wise R.A. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci. 2009, 32(10):517-524.
60. Woods R.P., Mazziotta J.C., Cherry S.R. MRI-PET registration with automated algorithm. J. Comput. Assist. Tomogr. 1993, 17(4):536-546.
61. Zack M., Poulos C.X. Parallel roles for dopamine in pathological gambling and psychostimulant addiction. Curr Drug Abuse Rev. 2009, 2(1):11-25.